Brief: Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R)
25/06/2025 13:24
June 25 (Reuters) - Amneal Pharmaceuticals Inc AMRX.O: AMNEAL HIGHLIGHTS POSITIVE TOPLINE RESULTS FROM CONFIRMATORY CLINICAL STUDY OF BIOSIMILAR CANDIDATE TO XOLAIR(R) (OMALIZUMAB), DEVELOPED BY KASHIV BIOSCIENCES AMNEAL PHARMACEUTICALS INC - ADL-018 CLINICAL STUDY ACHIEVES PRIMARY AND SECONDARY ENDPOINTS AMNEAL PHARMACEUTICALS INC - BLA FOR ADL-018 EXPECTED TO BE SUBMITTED TO FDA IN Q4 2025 Source text: ID:nGNXktkYK Further company coverage: AMRX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Amneal Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-3M Company, Constellation Energy, Metropolitan Bank Holding
US FDA is working with manufacturers to boost estrogen patch supply amid access concerns (updated)
U.S. RESEARCH ROUNDUP- Intuit, MongoDB, Zscaler
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Amneal Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary